CD4 and neoplasm: Through the establishment of a solid tumor model in mice, it was found that PSP+APS can significantly increase the percentage of CD3(+) and CD4(+) T lymphocytes in tumor tissues, the ratio of CD4(+)/CD8(+), and IL-2 in spleen and Bax/IL-2R expression.